INmune Bio Inc. - Common stock (NQ:INMB)

1.940 +0.010 (+0.52%)

Delayed Quote Updated: 4:00 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about INmune Bio Inc. - Common stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Which stocks are moving on Monday? ↗

June 30, 2025

Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements.

Via Chartmill

Alzheimer's Setback Hits INmune Bio Stock, But FDA Hopes Remain ↗

June 30, 2025

INmune Bio's Alzheimer's drug XPro showed targeted benefits in patients with brain inflammation, but misses the main trial endpoint.

Via Benzinga

Dow Gains Over 100 Points; Chicago PMI Weakens In June ↗

June 30, 2025

Via Benzinga

Topics Stocks

Gapping stocks in Monday's session ↗

June 30, 2025

The session on Monday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.

Via Chartmill

Earnings Scheduled For May 8, 2025 ↗

May 08, 2025

Via Benzinga

What to Expect from INmune Bio's Earnings ↗

March 26, 2025

Via Benzinga

INmune Bio Stock Slumps After Alzheimer’s Drug Falls Short In Mid-Stage Trial ↗

June 30, 2025

The primary endpoint of the study was not met in the intent-to-treat population, the company said.

Via Stocktwits

Get insights into the top gainers and losers of Monday's pre-market session. ↗

June 30, 2025

Discover the top movers in Monday's pre-market session and stay informed about market dynamics.

Via Chartmill

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

June 30, 2025

Via Benzinga

INmune Bio Reports Key Findings from Phase 2 MINDFuL Trial of XPro™ in Early Alzheimer’s Disease

June 30, 2025

From INmune Bio, Inc.

Via GlobeNewswire

Why Venus Concept Shares Are Trading Higher By Over 32%; Here Are 20 Stocks Moving Premarket ↗

June 30, 2025

Via Benzinga

Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗

June 27, 2025

Here are the top movers in Friday's session, showcasing the stocks with significant price changes.

Via Chartmill

INmune Bio, Inc. Announces Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

June 27, 2025

From INmune Bio, Inc.

Via GlobeNewswire

INmune Bio Stock Soars Friday On Alzheimer's Treatment Hopes ↗

June 27, 2025

INmune Bio stock rose sharply on high volume ahead of topline Phase 2 trial data for XPro in early Alzheimer's, expected on June 30.

Via Benzinga

Let's uncover which stocks are experiencing notable gaps during today's session. ↗

June 27, 2025

Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Friday. Let's explore the market movements and identify the stocks with significant gaps.

Via Chartmill

Stay updated with the stocks that are on the move in today's pre-market session. ↗

June 27, 2025

The US market is yet to commence its session on Friday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.

Via Chartmill

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

June 27, 2025

Via Benzinga

INmune Bio Skyrockets After-Hours On Alzheimer’s Trial Buzz; Retail Bulls Bet Big Before Data Reveal Next Week ↗

June 27, 2025

INmune is also developing XPro for treatment-resistant depression and exploring other immune-driven conditions like cancer and rare skin disorders.

Via Stocktwits

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

June 26, 2025

Via Benzinga

Get insights into the top gainers and losers of Thursday's after-hours session. ↗

June 26, 2025

After the closing bell on Thursday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.

Via Chartmill

INmune Bio Inc. to Announce Top Line Results from MINDFuL Phase 2 Trial in Early Alzheimer’s on Monday, June 30th

June 26, 2025

From INmune Bio, Inc.

Via GlobeNewswire

XPro™ Reduces Amyloid and Enhances Behavior Post Traumatic Brain Injury in an Animal Model of Alzheimer’s Disease: Supported by Department of Defense

June 10, 2025

From INmune Bio, Inc.

Via GlobeNewswire

INmune Bio Inc. Announces Attendance at the 2025 RBC Capital Markets Global Healthcare Conference

May 14, 2025

From INmune Bio, Inc.

Via GlobeNewswire

INmune Bio Inc. to Report First Quarter 2025 Financial Results and Provide Corporate Update on Thursday, May 8th

May 05, 2025

From INmune Bio, Inc.

Via GlobeNewswire

Why Calix Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket ↗

April 22, 2025

Via Benzinga

INmune Bio Receives Favorable Patentability Opinion for CORDStrom™ Platform Technology

April 16, 2025

From INmune Bio, Inc.

Via GlobeNewswire

INmune Bio Partners with Cell and Gene Therapy Catapult to Scale Up CORDStrom™ Manufacturing for Commercial Readiness

April 14, 2025

From INmune Bio, Inc.

Via GlobeNewswire

INmune Bio Inc. Presents Baseline Demographics and Disease Profiles of Participants in the MINDFuL Phase II Study

April 01, 2025

From INmune Bio, Inc.

Via GlobeNewswire

INmune Bio Inc. to Report Fourth Quarter 2024 Financial Results and Provide Corporate Update on March 27, 2025

March 24, 2025

From INmune Bio, Inc.

Via GlobeNewswire

Earnings Scheduled For March 27, 2025 ↗

March 27, 2025

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.